Components of Measurement Uncertainty from Representative Patient Vial (Sample 1)
| Uncertainty | Type A (methods 1 and 2) | Type B (method 1) | Type B (methods 1 and 2) | Type B (method 2) |
|---|---|---|---|---|
| Net peak area | 2.50% | |||
| Glass density and thickness (intervial variation) | 0.40% | |||
| Monte Carlo statistical uncertainty | 0.05% | |||
| Glass density and thickness (intravial variation) | 0.70% | |||
| High-density polyethylene density and thickness | 0.12% | |||
| Volume and activity-distribution effects | 0.50% | 0.91% | ||
| Efficiency calibration (energy interpolation) | 1.50% | |||
| Efficiency calibration (traceable source activities) | 1.16% | |||
| Positron range effects (simulated vs. 90Y) | 1.28% | |||
| Dead-time correction | 0.10% | |||
| 90Y positron branching ratio | 1.48% | |||
| Positron range effects (18F vs. 90Y) | 0.75% | |||
| 18F activity calibration | 1.00% | |||
| 18F decay correction and residual | 0.63% | |||
| Total | 2.50% | 2.45% | 1.54% | 1.67% |
| Average of methods 1 and 2 | 3.29% |